Keudell Morrison Wealth Management Acquires New Position in AbbVie Inc. $ABBV

Keudell Morrison Wealth Management purchased a new stake in AbbVie Inc. (NYSE:ABBV) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 19,963 shares of the company’s stock, valued at approximately $4,561,000. AbbVie accounts for about 1.0% of Keudell Morrison Wealth Management’s investment portfolio, making the stock its 21st largest holding.

Other hedge funds also recently made changes to their positions in the company. Eclectic Associates Inc. ADV boosted its stake in shares of AbbVie by 0.8% in the 4th quarter. Eclectic Associates Inc. ADV now owns 5,852 shares of the company’s stock valued at $1,337,000 after purchasing an additional 45 shares in the last quarter. Weil Company Inc. lifted its stake in AbbVie by 2.3% in the third quarter. Weil Company Inc. now owns 2,026 shares of the company’s stock worth $469,000 after purchasing an additional 46 shares during the last quarter. Hardin Capital Partners LLC boosted its position in AbbVie by 1.4% during the fourth quarter. Hardin Capital Partners LLC now owns 3,321 shares of the company’s stock valued at $759,000 after buying an additional 46 shares during the period. Dogwood Wealth Management LLC grew its stake in shares of AbbVie by 10.8% during the fourth quarter. Dogwood Wealth Management LLC now owns 473 shares of the company’s stock valued at $108,000 after buying an additional 46 shares during the last quarter. Finally, Quantum Private Wealth LLC increased its holdings in shares of AbbVie by 2.0% in the fourth quarter. Quantum Private Wealth LLC now owns 2,376 shares of the company’s stock worth $543,000 after buying an additional 46 shares during the period. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Allergan Aesthetics, AbbVie’s aesthetics unit, received a positive CHMP opinion in Europe for Boey® (trenibotulinumtoxinE) to treat moderate to severe glabellar lines, a step that could expand AbbVie’s aesthetics franchise if formal approval follows. Article: Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults
• Positive Sentiment: AbbVie said it will present new oncology data at ASCO 2026, highlighting momentum across its next-generation cancer pipeline in solid tumors and blood cancers, which supports longer-term growth expectations. Article: AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
• Positive Sentiment: Piper Sandler reiterated an Overweight rating and raised its price target on AbbVie, citing strength in the company’s inflammatory bowel disease pipeline and Skyrizi-related progress. Article: AbbVie Inc. (ABBV) Positioned for Long-Term Gains with IBD Pipeline Strength
• Neutral Sentiment: Analyst-style articles on undervaluation may offer some support to investor sentiment, but they do not appear to be direct company-specific catalysts for ABBV. Article: 3 Stocks That May Be Undervalued By The Market In May 2026
• Negative Sentiment: AbbVie also faces some headline risk after reports that its patent plea for the hepatitis C drug Mavyret was rejected in India, which could weigh on sentiment around parts of its older portfolio. Article: AbbVie’s Patent Plea for Hepatitis C Therapy Mavyret Rejected in India

AbbVie Price Performance

ABBV stock opened at $214.86 on Friday. The stock has a market capitalization of $379.60 billion, a P/E ratio of 105.84, a P/E/G ratio of 0.73 and a beta of 0.32. AbbVie Inc. has a 1-year low of $180.25 and a 1-year high of $244.81. The business has a fifty day moving average price of $208.95 and a 200-day moving average price of $219.71.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, topping the consensus estimate of $2.59 by $0.06. The company had revenue of $15 billion during the quarter, compared to the consensus estimate of $14.72 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.AbbVie’s revenue for the quarter was up 12.4% on a year-over-year basis. During the same period last year, the company earned $2.46 EPS. As a group, analysts anticipate that AbbVie Inc. will post 14.3 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on ABBV shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $240.00 price target on shares of AbbVie in a research note on Thursday, April 30th. The Goldman Sachs Group reissued a “neutral” rating and issued a $223.00 price target on shares of AbbVie in a research report on Wednesday, January 28th. BMO Capital Markets reaffirmed an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. William Blair reissued an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Finally, Morgan Stanley lifted their price target on AbbVie from $270.00 to $278.00 and gave the stock an “overweight” rating in a research report on Thursday, April 30th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, AbbVie has an average rating of “Moderate Buy” and an average target price of $253.43.

Insider Buying and Selling

In other news, SVP David Ryan Purdue sold 5,230 shares of the firm’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president directly owned 2,654 shares in the company, valued at $619,868.24. This trade represents a 66.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president directly owned 38,137 shares in the company, valued at approximately $8,771,510. This represents a 36.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.06% of the stock is owned by corporate insiders.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.